Skip to main content
. Author manuscript; available in PMC: 2017 Feb 1.
Published in final edited form as: Pediatr Crit Care Med. 2016 Feb;17(2):101–109. doi: 10.1097/PCC.0000000000000613

Figure 1.

Figure 1

(A) AVDSf at PARDS onset and at 24 hours in survivors and non-survivors. Data is presented as medians and IQR. P-value represents Wilcoxon rank sum tests. (B) ROC curves for AVDSf at PARDS onset (AUROC 0.76, 95% CI 0.66 to 0.85, p < 0.001) and 24 hours after PARDS onset (AUROC 0.55, 95% CI 0.42 to 0.68, p = 0.429).